Edition:
United Kingdom

Peregrine Pharma reports Q2 shr loss $0.31


Monday, 11 Dec 2017 

Dec 11 (Reuters) - Peregrine Pharmaceuticals Inc ::PEREGRINE PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2018 AND RECENT DEVELOPMENTS.Q2 LOSS PER SHARE $0.31.- COMPANY MAINTAINS ITS MANUFACTURING REVENUE GUIDANCE FOR FULL FY 2018 OF $50 MILLION - $55 MILLION.- CONSOLIDATED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS WAS $14.1 MILLION OR $0.31 PER SHARE, FOR Q2 OF FY 2018. 

Company Quote

4.33
0.02 +0.46%
18 Apr 2019